The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -2,680,860 |
| Share-based expense | 64,787 |
| Prepaid expenses and other | -255,660 |
| Other long-term assets | 0 |
| Accounts payable, accrued expenses and other current liabilities | 73,762 |
| Net cash used in operating activities | -2,286,651 |
| Net proceeds from issuance of common stock in october 2025 underwritten public offering | 4,004,715 |
| Net cash provided by financing activities | 4,004,715 |
| Net change in cash | 1,718,064 |
| Cash at beginning of period | 6,165,568 |
| Cash at end of period | 7,883,632 |
Xenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. (XBIO)